Welcome to our dedicated page for Zhengye Biotechnology Holding SEC filings (Ticker: ZYBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zhengye Biotechnology Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zhengye Biotechnology Holding's regulatory disclosures and financial reporting.
Zhengye Biotechnology Holding Limited reports recent unusual price and volume movements in its Class A ordinary shares and states it is not aware of any material non-public information about its business, financial condition, or operations that would explain this trading activity. Management indicates operations continue in the ordinary course and that there have been no undisclosed corporate developments or transactions that would account for the volatility.
The company has contacted Nasdaq about the trading and will cooperate with Nasdaq and other regulators as appropriate. It cautions shareholders and prospective investors to exercise care when evaluating its securities and to rely on information in its U.S. Securities and Exchange Commission filings. Zhengye also describes its veterinary vaccine business in China and selected overseas markets.
Zhengye Biotechnology Holding Ltd director and major shareholder Han Zhenfa has filed an initial Form 3 reporting indirect holdings of the company’s ordinary shares. The filing lists 40,000,000 ordinary shares held by Securingium Holding Limited, 2,278,752 shares held by Vanguards Skyline Holdings Limited, and 684,996 shares held by VVAX Holdings Limited.
These entities are BVI and Chinese holding vehicles that are owned or controlled through structures in which Han is the settlor, beneficiary, protector, or managing partner, reflecting his status as a more than 10% beneficial owner.
Zhengye Biotechnology Holding Ltd filed an initial insider ownership report for Vice General Manager Cheng Yuhong on Form 3. This filing identifies Cheng as an officer of the company but shows no reported transactions, no derivative positions, and no current holdings entries at the time of this statement.
Zhengye Biotechnology Holding Ltd filed a Form 3 for Co-Chief Executive Officer Song Songlin, serving as an initial statement of beneficial ownership. The filing shows no reportable transactions or derivative positions and does not list any buy, sell, acquisition, or disposition activity.
Zhengye Biotechnology Holding Ltd filed an initial Form 3 for Chief Financial Officer Wang Ping. This filing establishes Wang Ping as a reporting insider of ZYBT. It does not list any buy, sell, or derivative transactions, and no holdings details appear in the provided data.
Zhengye Biotechnology Holding Ltd director Jiang Ping (PiJi) filed an initial Form 3 ownership report for ticker ZYBT. The filing lists Jiang Ping as a director but not a ten percent owner, and shows no reported purchases, sales, or other transactions in the company’s securities.
Zhengye Biotechnology Holding Limited reported that Nasdaq has notified the company it is not in compliance with the exchange’s minimum bid price rule. The closing bid for its Class A ordinary shares stayed below $1.00 for 30 consecutive business days through May 28, 2026.
The shares remain listed and continue trading on the Nasdaq Capital Market under the symbol ZYBT. Zhengye has 180 calendar days, until November 25, 2026, for its shares to close at or above $1.00 for at least 10 consecutive business days to regain compliance.
If the company cannot meet this requirement by that date, it may receive an additional 180-day grace period if it satisfies other listing standards and formally outlines a plan to cure the deficiency, potentially including a reverse share split. The company states its business operations are not affected by the notice.
Zhengye Biotechnology Holding Limited, a Cayman Islands holding company, files its annual Form 20‑F covering the year ended December 31, 2025. It reports 47,391,376 ordinary shares outstanding as of December 31, 2025, each with a par value of $0.000025. Subsequent to year‑end, these ordinary shares were reclassified into Class A and Class B Ordinary Shares, creating a dual‑class structure with different voting rights.
The company explains that investors hold equity in the Cayman parent, which indirectly owns PRC and Hong Kong operating subsidiaries. It highlights extensive legal and operational risks from doing business in China, including evolving cybersecurity and data‑security oversight, anti‑monopoly review, and new CSRC overseas listing filing rules. Management notes completion of a CSRC overseas listing filing and states that, based on PRC legal advice, current operations do not trigger cybersecurity review thresholds, though future regulatory changes could affect operations or the value of Class A Ordinary Shares.
The filing also discusses HFCAA and related U.S. laws that could lead to trading prohibitions if the PCAOB cannot fully inspect the company’s auditor, cross‑border cash transfer and dividend restrictions under PRC foreign‑exchange rules, and potential PRC tax residency and withholding tax consequences. Financial statements are prepared in Renminbi and translated at an exchange rate of RMB6.9931 to US$1.00, with the company warning that currency fluctuations may materially affect results and the value of U.S.‑traded shares.
Zhengye Biotechnology Holding Ltd director Hu Qiyi has filed an initial Form 3, which is the required statement of beneficial ownership for insiders. The provided data shows no reported transactions or derivative positions, indicating this filing is purely administrative and does not reflect any recent trading activity.
Zhengye Biotechnology Holding Ltd director Li Guohan filed an initial Form 3 insider ownership report. The filing shows no reported purchases, sales, exercises, gifts, or other transactions, and no derivative positions listed, serving as a baseline disclosure of insider status.